Importantly, the inhibition of SEC23A has been shown to promote prostate cancer metastasis [36,37,38], and SEC23A expression is decreased in tumor tissues of patients with metastatic castration-resistant disease, in comparison to primary prostate cancer and benign tissue [39] (Figure 3C). This evidence concerns the gene SEC23A and prostate carcinoma.